Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials

References

• Rotstein C, Evans G, Born A, et al. Clinical practice guidelines for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in adults. Can J Infect Dis Med Microbiol. 2008;19(1):19–53. doi: 10.1155/2008/593289
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multi-drug resistant gram-negative bacilli. Drugs. 2019;79(3):271–289. doi: 10.1007/s40265-019-1055-2
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(20):159–177. doi: 10.1007/s40265-013-0013-7
   PubMedGoogle Scholar
• Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs. 2018;78(1):65–98. doi: 10.1007/s40265-017-0851-9
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline: a novel fluorocycline antibacterial agents. Drugs. 2016;76(5):567–588. doi: 10.1007/s40265-016-0545-8
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Reviews In Antiinfective Therapy. 2012;10(4):459–473. doi: 10.1586/eri.12.25
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Sniezek G, Schweizer F, et al. A review of ceftaroline: a novel broad spectrum cephalosporin with activity against MRSA. Drugs. 2009;69(7):809–831. doi: 10.2165/00003495-200969070-00003
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Adam HJ, Baxter MR, et al. 42936 pathogens from Canadian hospitals: 10 years of results (2007-2016) from the CANWARD surveillance study. 2007-2016. J Antimicrob Chemother. 2019;74(Supplement 4):5–21. doi: 10.1093/jac/dkz283
   Google Scholar
• Walkty A, Lagace-Wiens PRS, Adam H, et al. Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: results of the CANWARD study, 2008-2012. Diagn Microbiol Infect Dis. 2017;87(1):60–63. doi: 10.1016/j.diagmicrobio.2016.10.003
   PubMed Web of Science ®Google Scholar
• Denisuik AJ, Garbutt LA, Golden AR, et al. Antimicrobial resistant pathogens in Canadian ICUs: results of the CANWARD 2007-2016 study. J Antimicrob Chemother. 2019;74(3):645–653. doi: 10.1093/jac/dky477
   PubMed Web of Science ®Google Scholar
• Lagace-Wiens PRS, Adam HJ, Poutanen S, et al. Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results on the CANWARD study 2007-2016. J Antimicrob Chemother. 2019;74(Supplement 4):22–31. doi: 10.1093/jac/dkz284
   PubMedGoogle Scholar
• Denisuik AJ, Karlowsky JA, Adam HJ, et al. Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007-2016. J Antimicrob Chemother. 2019;74(Supplement 4):64–71. doi: 10.1093/jac/dkz289
   Google Scholar
• Karlowsky JA, Walkty A, Golden AR, et al. ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007–18. J Antimicrob Chemother. 2021; Aug 11;76(11):2815–2824. doi: 10.1093/jac/dkab269
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Adam HJ, Golden AR, et al. Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-2015. J Antimicrob Chemother. 2018;73(Suppl 7):5–11. doi: 10.1093/jac/dky156
   Google Scholar
• Nichol KA, Adam HJ, Golding GR, et al. Characterization of MRSA in Canada from 2007-2016. J Antimicrob Chemother. 2019;74(Supplement 4):55–63. doi: 10.1093/jac/dkz288
   Google Scholar
• Golden AR, Baxter MR, Davidson RJ, et al. Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-2016. J Antimicrob Chemother. 2019;74(Supplement 4):39–47. doi: 10.1093/jac/dkz286
   Google Scholar
• Zhanel GG, Lynch JP, Adam HJ. Streptococcus pneumoniae serotyping and antimicrobial susceptibility: assessment of vaccine efficacy in Canada after the introduction of PCV13. J Antimicrob Chemother. 2023;78(suppl 1):2–7. doi: 10.1093/jac/dkad064
   Google Scholar
• Adam HJ, Karlowsky JA, Baxter MR, et al. Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-2020. J Antimicrob Chemother. 2023;78(suppl 1):17–25. doi: 10.1093/jac/dkad066
   Google Scholar
• Alford MA, Karlowsky JA, Adam HJ, et al. Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-2020. J Antimicrob Chemother. 2023;78(suppl 1):8–16. doi: 10.1093/jac/dkad065
   Google Scholar
• Lynch JP, Zhanel GG. Escalation of antimicrobial resistance among MRSA part 1: focus on global spread. Exp Rev Antiinfective Ther. 2022 Dec;12(2):1–15. doi: 10.1080/14787210.2023.2154653
   Google Scholar
• Lynch JP. Zhanel GG escalation of antimicrobial resistance among MRSA part 2: focus on treatment. Exp Rev Antiinfective Ther. 2022 Dec;21(2):1–12. doi: 10.1080/14787210.2023.2154654
   PubMed Web of Science ®Google Scholar
• Lynch JP, Clark NM, Zhanel GG. Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases. Exp Opin Pharmacother. 2021;22(11):1455–1473. doi: 10.1080/14656566.2021.1904891
   PubMed Web of Science ®Google Scholar
• Lynch JP, Zhanel GG. Pseudomonas aeruginosa pneumonia: evolution of antimicrobial resistance and implications for therapy. Sem Resp Crit Care Med. 2022;43(1):97–124. doi: 10.1055/s-0041-1740109
   PubMedGoogle Scholar
• Lynch JP, Clark NM, Zhanel GG. Infections due to Acinetobacter baumannii in the ICU: treatment options. Sem Resp Crit Care Med. 2022;43(1):97–124. doi: 10.1055/s-0041-1741019
   PubMedGoogle Scholar
• Zhanel GG, Lam A, Schweizer F, et al. Ceftobiprole: a review of a broad spectrum and anti-MRSA cephalosporin. Amer J Clin Dermatol. 2008;9(4):245–254. doi: 10.2165/00128071-200809040-00004
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Voth D, Nichol K, et al. Pharmacodynamics activity of ceftobiprole compared to vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother. 2009;64(2):364–369. doi: 10.1093/jac/dkp176
   PubMed Web of Science ®Google Scholar
• Salem AH, Zhanel GG, Ibrahim SA, et al. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol. 2014;41(6):437–443. doi: 10.1111/1440-1681.12195
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Chung P, Adam HJ, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74(1):31–51. doi: 10.1007/s40265-013-0168-2
   PubMed Web of Science ®Google Scholar
• Walkty A, Adam H, Baxter M, et al. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study 2008-2016. J Antimicrob Chemother. 2020;73(3):703–708. doi: 10.1093/jac/dkx468
   Web of Science ®Google Scholar
• Zhanel GG, Zhanel MA, Karlowsky JA. Intravenous fosfomycin: an assessment of its potential for use in the treatment of systemic infections in Canada. Can J Infect Dis Med Microbiol. 2018;25:8912039.11.
   Google Scholar
• Zhanel GG, Calic D, Schweizer F, et al. Dalbavancin, oritavancin and telavancin: a comparative review. Drugs. 2010;70(7):859–886. doi: 10.2165/11534440-000000000-00000
   PubMed Web of Science ®Google Scholar
• Truc T, Tran A, Sara H. New perspectives on antimicrobial agents: long-acting lipoglycopeptides. Antimicrob Agents Chemother. 2022;66(6):1–18. doi: 10.1128/aac.02614-20
   Web of Science ®Google Scholar
• Monteagudo-Martínez N, Solís-García Del Pozo J, Nava E, et al. Acute bacterial skin and skin-structure infections, efficacy of dalbavancin: a systematic review and meta-analysis. Exp Rev Antiinfect Ther. 2022;20(11):1477–1489. doi: 10.1080/14787210.2021.1828865
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179. doi: 10.1056/NEJMoa1310480
   PubMed Web of Science ®Google Scholar
• Gatti M, Andreoni M, Pea F. Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs. Drug Design Develop Therapy. Volume 15:3349–3378. doi: 10.2147/DDDT.S313756
   Web of Science ®Google Scholar
• Rappo U, Dunne MW, Puttagunta S, et al. Epithelial lining fluid and plasma concentrations of dalbavancin in healthy adults after a single 1,500-milligram infusion. Antimicrob Agents Chemother. 2019;63(11):1–6. doi: 10.1128/AAC.01024-19
   Web of Science ®Google Scholar
• Zhanel GG, Baxter M, Wong M, et al. Real life experience with IV fosfomycin in Canada: results from the CLEAR (Canadian leadership on antimicrobial real-life usage) registry. J Glob Antimicrob Resis. 2023;3:171–176. doi: 10.1016/j.jgar.2023.03.010
   Google Scholar
• Tamma PD, Bonomo RA, Stiefel U. The role of intravenous fosfomycin: finding our way out of Dante’s forest dark. JAMA Netw Open. 2022;5(1):e2138691. doi: 10.1001/jamanetworkopen.2021.38691
   PubMed Web of Science ®Google Scholar
• Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, et al. Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial. JAMA Netw Open. 2022;5(1):e2137277. doi: 10.1001/jamanetworkopen.2021.37277
   PubMed Web of Science ®Google Scholar
• Zirpe KG, Mehta Y, Pandit R, et al. A real-world study on prescription pattern of fosfomycin in critical care patients. Ind Crit Care Med. 2021;25(9):1055–1058. doi: 10.5005/jp-journals-10071-23958
   PubMed Web of Science ®Google Scholar
• Abdallaha AK, Elajezc R, Tawheeda B, et al. Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat gram-negative bacterial infections. J Infect Pub Health. 2021;14(11):1620–1622. doi: 10.1016/j.jiph.2021.09.025
   PubMed Web of Science ®Google Scholar
• Ballouz T, Zeenny RM, Haddad N, et al. Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon. J Infect Dev Ctries. 2021;15(9):1308–1313. doi: 10.3855/jidc.14125
   PubMed Web of Science ®Google Scholar
• Antonello RM, Principe L, Maraolo AE, et al. Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies. Antibiotics. 2020;9(8):1–74. doi: 10.3390/antibiotics9080500
   Google Scholar
• Putensen C, Ellger B, Sakka SG, et al. Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection. 2019;47(5):827–836. doi: 10.1007/s15010-019-01323-4
   PubMed Web of Science ®Google Scholar
• Bodmann KF, Venditti M, Bal A, et al. Intravenous (IV) fosfomycin for the treatment of severely infected patients (FORTRESS): an update from a European non-interventional and prospective clinical study: European Congress of clinical Microbiology and Infectious Diseases (ECCMID). 2021. online, poster 475.
   Google Scholar
• Zhanel GG, Kosar J, Baxter M, et al. Real life experience with ceftobiprole in Canada: results from the CLEAR (Canadian leadership on antimicrobial real-life usage) registry. J Glob Antimicrob Resis. 2021;24:335–339. doi: 10.1016/j.jgar.2021.01.014
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Weite T, File TM, et al. A randomized double-blind trial comparing ceftobiprole medocaril with ceftriaxone with and without linezolid for the treatment of patients with community acquired pneumonia requiring hospitalization. Int J Antimicrob Agents. 2012;39(3):240–246. doi: 10.1016/j.ijantimicag.2011.11.005
   PubMed Web of Science ®Google Scholar
• Awad S, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59(1):51–61. doi: 10.1093/cid/ciu219
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Mazza MC, et al. Real-life experience with ceftobiprole in a tertiary-care hospital. J Glob Antimicrob Resist. 2020;22:386–390. doi: 10.1016/j.jgar.2020.03.010
   PubMed Web of Science ®Google Scholar
• Mahmoud E, Al Mansour S, Bosaeed M, et al. Ceftobiprole for treatment of MRSA blood stream infection: a case series. Infect Drug Resist 2020;13: 2667–2672. doi: 10.2147/IDR.S254395
   PubMed Web of Science ®Google Scholar
• Crapis M, Venturini S, Siega PD, et al. Ceftobiprole and pneumonia in adults admitted to emergency department is it time to assess the new therapeutic algorithm. J Chemother. 2020 Sep;30:1–6.
   Google Scholar
• Hamed K, Engelhardt M, Jones ME, et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, phase III trial. Fut Microbiol. 2020;15(1):35–48. doi: 10.2217/fmb-2019-0332
   PubMed Web of Science ®Google Scholar
• Scheeren TWL, Weite T, Saulay M, et al. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials. BMC Infect Dis. 2019;19(1):195–201. doi: 10.1186/s12879-019-3820-y
   PubMedGoogle Scholar
• Zhanel GG, Dhami R, Baxter M, et al. Real life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian leadership on antimicrobial real-life usage) registry. J Glob Antimicrob Resis. 2021 Jun;25:346–350. doi: 10.1016/j.jgar.2021.03.025
   PubMed Web of Science ®Google Scholar
• Timsit JF, Huntington JA, Wunderink RG, et al. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospitalacquired bacterial pneumonia: subset analysis of the ASPECTNP randomized, controlled phase 3 trial. Crit Care. 2021;25(1):290–304. doi: 10.1186/s13054-021-03694-3
   PubMed Web of Science ®Google Scholar
• Nail J, Puzniak L, Critchlow S, et al. Cost effectiveness of ceftolozane/tazobactam compared with meropenem for the treatment of patients with ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Infect Dis Ther. 2021;10(2):939–954. doi: 10.1007/s40121-021-00436-4
   PubMed Web of Science ®Google Scholar
• Chi Y, Xu J, Bai N, et al. The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies. Exp Rev Antiinfect Ther. 2023;21(2):189–201. doi: 10.1080/14787210.2023.2166931
   PubMed Web of Science ®Google Scholar
• Cultera R, Libanore M, Barozzi A, et al. Ceftolozane/tazobactam and ceftazidime/avibactam for multidrug-resistant gram-negative infections in immunocompetent patients: a single center retrospective study. Antibiotics. 2020;9(10):640–645. doi: 10.3390/antibiotics9100640
   Google Scholar
• Bosaeed M, Ahmad A, Alali A, et al. Experience with ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections in Saudi tertiary care center. Infect Dis Res Treat. 2020;13:1–5. doi: 10.1177/1178633720905977
   Google Scholar
• Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real world experience with ceftolozane/tazobactam for multi-drug resistant gram-negative bacterial infections. Antimicrob Agents Chemother. 2020;64(4):1–12. doi: 10.1128/AAC.02291-19
   Web of Science ®Google Scholar
• Vena A, Giacobbe DR, Mussini C, et al. Clinical efficacy of ceftolozane-tazobactam versus other active agents for the treatment of bacteremia and nosocomial pneumonia due to drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020;71(7):1799–1801. doi: 10.1093/cid/ciaa003
   PubMed Web of Science ®Google Scholar
• Bassetti M, Castaldo N, Cattelan A, et al. Ceftolozane/Tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Intern J Antimicrob Agents. 2019;7153(4):408–415. doi: 10.1016/j.ijantimicag.2018.11.001
   Google Scholar
• Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane/tazobactam for the treatment of multi-drug resistant Pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis. 2018;31(5):1–5. doi: 10.1093/ofid/ofy210.2035
   Google Scholar
• Gentile I, Buonomo AR, Corcione S, et al. CEFTO-CURE study: CEFTObiprole clinical use in Real-lifE – a multi-centre experience in Italy. Int J Antimicrob Agent. 2023;62(1):1–10. doi: 10.1016/j.ijantimicag.2023.106817
   Web of Science ®Google Scholar
• Bavaro DF, Belati A, Diella L, et al. Loading dose plus continuous/extended infusion versus intermittent bolus of β-lactams for the treatment of gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study. J Antimicrob Chemother. 2023;78(9):2175–2184. doi: 10.1093/jac/dkad215
   PubMed Web of Science ®Google Scholar
• Roberts JA, Croom K, Adamakoh N. Continuous infusion of beta-lactam antibiotics: narrative review of systematic reviews, and implications for outpatient parenteral antibiotic therapy. Exp Rev Antiinfect Ther. 2023;21(4):375–385. doi: 10.1080/14787210.2023.2184347
   PubMed Web of Science ®Google Scholar
• Gatti M, Pea F. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat- gram-negative infections with novel beta-lactams. Exp Rev Antiinfect Ther. 2023;21(2):149–166. doi: 10.1080/14787210.2023.2169131
   PubMed Web of Science ®Google Scholar
• Pilmis B, Petitjean G, Lesprit P, et al. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2019;38(8):1457–1461. doi: 10.1007/s10096-019-03573-4
   PubMed Web of Science ®Google Scholar
• Sheffield M, Nelson D, O’Neal M, et al. Use of continuous-infusion ceftolozane/tazobactam for resistant gram-negative bacterial infections: a retrospective analysis and brief review of the literature. Int J Antimicrob Agents. 2020;56(5):106158. doi: 10.1016/j.ijantimicag.2020.106158
   PubMed Web of Science ®Google Scholar
• Antonello RM, Di Bella S, Maraolo AE, et al. Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies vivo and clinical studies. Eur J Clin Microbiol Infect Dis. 2021;40(6):1117–1126. doi: 10.1007/s10096-021-04181-x
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects: focus on aminoglycosides. Clin Pharmacokinet. 1994;27(5):377–392. doi: 10.2165/00003088-199427050-00005
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Ennis K, Vercaigne L, et al. Critical review of fluoroquinolones: focus on respiratory infections. Drugs. 2002;62(1):13–59. doi: 10.2165/00003495-200262010-00002
   PubMed Web of Science ®Google Scholar